Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on April 13, 2005
J Am Soc Nephrol 16: 1803-1810, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2004070597

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2004070597v1
16/6/1803    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weiner, D. E.
Right arrow Articles by Sarnak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiner, D. E.
Right arrow Articles by Sarnak, M. J.

Epidemiology and Outcomes

Effects of Anemia and Left Ventricular Hypertrophy on Cardiovascular Disease in Patients with Chronic Kidney Disease

Daniel E. Weiner*, Hocine Tighiouart{dagger}, Panagiotis T. Vlagopoulos*, John L. Griffith{dagger}, Deeb N. Salem{ddagger}, Andrew S. Levey* and Mark J. Sarnak*

Divisions of * Nephrology, {dagger} Clinical Care Research, and {ddagger} Cardiology, Tufts-New England Medical Center, Boston, Massachusetts

Address correspondence to: Dr. Mark J. Sarnak, Division of Nephrology, Tufts-New England Medical Center, 750 Washington Street, Box 391, Boston, MA 02111. Phone: 617-636-1182; Fax: 617-636-2369; E-mail: msarnak{at}tufts-nemc.org

Received for publication July 25, 2004. Accepted for publication March 2, 2005.

Left ventricular hypertrophy (LVH) and anemia are highly prevalent in moderate chronic kidney disease (CKD). Because anemia may potentiate the adverse effects of LVH on cardiovascular outcomes, the effect of both anemia and LVH on outcomes in CKD was examined. Data from four community-based longitudinal studies were pooled: Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, Framingham Heart Study, and Framingham Offspring Study. Serum creatinine levels were calibrated indirectly across studies, and GFR was estimated using the Modification of Diet in Renal Disease equation. CKD was defined as GFR between 15 and 60 ml/min per 1.73 m2. LVH was based on electrocardiogram criteria. Anemia was defined as hematocrit <36% in women and 39% in men. The primary outcome was a composite of myocardial infarction, stroke, and death; a secondary cardiac outcome included only myocardial infarction and fatal coronary heart disease. Among 2423 patients with CKD, 96% had electrocardiogram and anemia data. Median follow-up was 102 mo. In adjusted analysis, LVH was associated with increased risk for composite and cardiac outcomes (hazard ratio [HR], 1.67 [95% confidence interval (CI), 1.34 to 2.07] and 1.62 [95% CI, 1.18 to 2.24], respectively), whereas anemia was associated with increased risk for the only composite outcome (HR, 1.51 [95% CI, 1.27 to 1.81]). The combination of anemia and LVH was associated with an increased risk for both study outcomes compared with individuals with neither risk factor (HR, 4.15 [95% CI, 2.62 to 6.56] and 3.92 [95% CI, 2.05 to 7.48]; P = 0.02 and 0.01 for interaction term, respectively). The combination of anemia and LVH in CKD identifies a high-risk population.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
B. B. Newsome, S. J. Onufrak, D. G. Warnock, and W. M. McClellan
Exploration of anaemia as a progression factor in African Americans with cardiovascular disease
Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3404 - 3411.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
S. Tomasello
Anemia of Chronic Kidney Disease
Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195.
[Abstract] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
D. E. Weiner, H. Tighiouart, E. F. Elsayed, J. L. Griffith, D. N. Salem, and A. S. Levey
Uric Acid and Incident Kidney Disease in the Community
J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1204 - 1211.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
P. Raggi and M. Kleerekoper
Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 836 - 843.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B.C. Astor, S. Yi, L. Hiremath, T. Corbin, V. Pogue, B. Wilkening, G. Peterson, J. Lewis, J.P. Lash, F. Van Lente, et al.
N-Terminal Prohormone Brain Natriuretic Peptide as a Predictor of Cardiovascular Disease and Mortality in Blacks With Hypertensive Kidney Disease: The African American Study of Kidney Disease and Hypertension (AASK)
Circulation, April 1, 2008; 117(13): 1685 - 1692.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
N. Joss, R. Patel, K. Paterson, K. Simpson, C. Perry, and C. Stirling
Anaemia is common and predicts mortality in diabetic nephropathy
QJM, October 1, 2007; 100(10): 641 - 647.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. M. Bertoli, L. M. Vila, M. Apte, B. J. Fessler, H. M. Bastian, J. D. Reveille, G. S. Alarcon, and for the LUMINA Study Group
Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual
Rheumatology, September 1, 2007; 46(9): 1471 - 1476.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
D. E. Weiner, H. Tighiouart, A. S. Levey, E. Elsayed, J. L. Griffith, D. N. Salem, and M. J. Sarnak
Lowest Systolic Blood Pressure Is Associated with Stroke in Stages 3 to 4 Chronic Kidney Disease
J. Am. Soc. Nephrol., March 1, 2007; 18(3): 960 - 966.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
T. B. Drueke, F. Locatelli, N. Clyne, K.-U. Eckardt, I. C. Macdougall, D. Tsakiris, H.-U. Burger, A. Scherhag, and the CREATE Investigators
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
N. Engl. J. Med., November 16, 2006; 355(20): 2071 - 2084.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. E. Imoagene-Oyedeji, S. E. Rosas, A. M. Doyle, S. Goral, and R. D. Bloom
Posttransplantation Anemia at 12 Months in Kidney Recipients Treated with Mycophenolate Mofetil: Risk Factors and Implications for Mortality
J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3240 - 3247.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
F. K. Port, R. L. Pisoni, J. Bommer, F. Locatelli, M. Jadoul, G. Eknoyan, K. Kurokawa, B. J. Canaud, M. P. Finley, and E. W. Young
Improving Outcomes for Dialysis Patients in the International Dialysis Outcomes and Practice Patterns Study
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 246 - 255.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP